WallStreetZenWallStreetZen

NASDAQ: DMAA
Drugs Made In America Acquisition Corp Earnings Dates, Reports, Calls

OverviewEarnings
RevenueDividendOwnership
Drugs Made In America Acquisition earnings were $6.1M for the trailing 12 months ending Jun 30, 2026, with 111.1% growth year over year. The latest DMAA earnings report on Jun 30, 2026 announced Q2 2026 earnings of $1.7M, down 12.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, DMAA reported annual earnings of $5.9M, with -2,222.8% growth.

DMAA past earnings growth

How has DMAA's earnings growth performed historically?

Company
111.11%
Industry
51.96%
Market
92.82%
DMAA's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
DMAA's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
DMAA's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

DMAA earnings history

Current Revenue
$0.0
Current Earnings
$6.1M
Current Profit Margin
0%

DMAA Return on Equity

Current Company
-83%
Current Industry
231.5%
Current Market
30.9%
DMAA's Return on Equity (-83%)... subscribe to Premium to read more.
High Return on Equity Performance

DMAA Return on Assets

Current Company
2.8%
Current Industry
-1.9%
DMAA is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when DMAA announces earnings.

DMAA Return on Capital Employed

Current Company
4.23%
Current Industry
-1.6%

DMAA vs Shell Company Stocks

TickerEBITDAEarningsY/Y EarningsEPS
DMAA$6.09M$6.09M+111.11%$0.19
NTWO$4.95M$4.95M-16.67%$0.20
HVII$2.64M$2.64M+10.00%$0.11
OACC$6.75M$6.75M+7.41%$0.29
VACI$2.80M$2.80MN/A$0.09
View Top Shell Company Stocks

Drugs Made In America Acquisition Earnings Reports & History FAQ

What were Drugs Made In America Acquisition's earnings last quarter?

Drugs Made In America Acquisition (NASDAQ: DMAA) reported Q2 2026 earnings per share (EPS) of $0.06, up 14.29% year over year. Total DMAA earnings for the quarter were $1.73 million. In the same quarter last year, Drugs Made In America Acquisition's earnings per share (EPS) was $0.07.

If you're new to stock investing, here's how to buy Drugs Made In America Acquisition stock.

Is Drugs Made In America Acquisition profitable or losing money?

As of the last Drugs Made In America Acquisition earnings report, Drugs Made In America Acquisition is currently profitable. Drugs Made In America Acquisition's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $6.09 million, a 83.68% increase year over year.

What was DMAA's earnings growth in the past year?

As of Drugs Made In America Acquisition's earnings date in Q3 2026, Drugs Made In America Acquisition's earnings has grown 111.11% year over year. This is 59.16 percentage points higher than the US Shell Companies industry earnings growth rate of 51.96%. DMAA earnings in the past year totalled $6.09 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.